卡维地洛降低门静脉压力用于食管静脉曲张出血一级预防的剂量反应研究
该回顾性研究纳入72例肝硬化患者,评估卡维地洛6.25 mg/d与12.5 mg/d对肝静脉压力梯度(HVPG)应答率的影响。6.25 mg/d时39%患者HVPG下降≥20%,增至12.5 mg/d后总应答率达53%;按Baveno VI标准(≥10%或≤12 mm Hg)总应答率为76%。6例患者因低血压/心动过缓不能耐受加量至12.5 mg/d,其中4例有腹水。
要点
- 卡维地洛6.25 mg/d时39%患者HVPG下降≥20%,12.5 mg/d时另有14%应答。
- 按Baveno VI标准,6.25 mg/d时56%应答,12.5 mg/d时另有33%应答,总应答率76%。
- 6例患者因低血压/心动过缓不能耐受加量至12.5 mg/d,其中4例有腹水。
核心结论
- 卡维地洛12.5 mg/d在降低HVPG方面比6.25 mg/d更有效,用于一级预防时76%患者达到HVPG下降≥10%的应答,但可能发生动脉低血压,尤其是有腹水的患者。
研究设计与样本
- 回顾性纳入2010年8月至2015年5月连续接受HVPG引导下卡维地洛治疗用于食管静脉曲张出血一级预防的肝硬化患者72例(Child A级37%、B级35%、C级28%)。
- 基线HVPG测量后给予卡维地洛6.25 mg/d,3-4周后评估HVPG应答(下降≥20%或≤12 mm Hg);无应答者加量至12.5 mg/d,再3-4周后行第三次HVPG测量。
- 同时按Baveno VI共识(HVPG下降≥10%或≤12 mm Hg)评估应答率,并评估收缩压(SAP)变化。
主要发现
- 卡维地洛6.25 mg/d时28例(39%)患者HVPG下降≥20%,加量至12.5 mg/d后另有10例(14%)应答,总应答率53%(38例)。
- 按Baveno VI标准,卡维地洛6.25 mg/d时40例(56%)应答,12.5 mg/d时另有24例(33%)应答,总应答率76%(55例)。
- 6例患者(其中4例有腹水)因低血压/心动过缓不能耐受加量至12.5 mg/d;其余患者在最终HVPG测量时均无SAP<90 mm Hg。
关键数值与推荐
- HVPG应答定义为HVPG下降≥20%或降至≤12 mm Hg。
- Baveno VI共识应答定义为HVPG下降≥10%或降至≤12 mm Hg。
- 卡维地洛剂量为6.25 mg/d和12.5 mg/d。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sequential measurements of hepatic venous pressure gradient (HVPG) are used to assess the haemodynamic response to nonselective betablockers (NSBBs) in patients with portal hypertension. AIMS: To assess the rates of HVPG response to different doses of carvedilol. METHODS: Consecutive patients with cirrhosis undergoing HVPG-guided carvedilol therapy for primary prophylaxis of variceal bleeding between 08/2010 and 05/2015 were retrospectively included. After baseline HVPG measurement, carvedilol 6.25 mg/d was administered and HVPG response (HVPG-decrease ≥20% or to ≤12 mm Hg) was assessed after 3-4 weeks. In case of nonresponse, carvedilol dose was increased to 12.5 mg/d and a third HVPG-measurement was performed after 3-4 weeks. We also assessed HVPG-response rates according to the Baveno VI consensus (HVPG decrease ≥10% or to ≤12 mm Hg) and changes in systolic arterial pressure (SAP). RESULTS: Seventy-two patients (Child A, 37%; B, 35%; C, 28%) were included. 28 (39%) patients achieved a HVPG-decrease ≥ 20% with carvedilol 6.25 mg/d and another 10 (14%) with carvedilol 12.5 mg/d. Forty (56%) patients had a HVPG decrease ≥10% with carvedilol 6.25 mg/d and 24 (33%) with carvedilol 12.5 mg/d. Thus, in total, a HVPG-response of ≥20% and ≥10% and was achieved in 38 (53%) and 55 (76%) and of patients respectively. Notably, 6 patients (n = 4 with ascites) did not tolerate an increase to 12.5 mg/d due to hypotension/bradycardia. However, none of the other patients had a SAP < 90 mm Hg at the final HVPG measurement. CONCLUSION: Carvedilol 12.5 mg/d was more effective than 6.25 mg/d in decreasing HVPG in primary prophylaxis. A total of 76% of patients achieved a HVPG-response of ≥ 10% to carvedilol 12.5 mg/d, however, arterial hypotension might occur, especially in patients with ascites.
引用
- Schwarzer R, Kivaranovic D, Paternostro R, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018. PMID: 29492989. doi:10.1111/apt.14576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。